FLUGEN, INC.
Live replication-deficient influenza virus (M2SR/BM2SR) vaccine platform encoding viral antigens from influenza A or B strains
- Sector
- Biotech
- Headquarters
- Madison, WI
- Founded
- 2007
- Latest Form D
- $8.2M, May 2020
- Total capital
- $35.8M
- Federal grants
- $3.8M
- 6 awards · 2015–2018
- Rank in peer group#251 of 514
- Private capital raised
- $31.9M
- 5 Form D · last May 2020
- 78 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 16
- 24 pending · first 2017
- Rank in peer group#14 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$8.2M
- Federal grantHealth and Human S · Phase II · Development of a novel highly effective influenza vaccine$656K
- Private capital raisedForm D · SEC · 4th filing$5.6M
- Federal grantHealth and Human S · Phase II · Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$1.1M
- Federal grantHealth and Human S · Phase II · Development of a novel highly effective influenza vaccine$834K
- Private capital raisedForm D · SEC · 3rd filing$5.5M
- Federal grantHealth and Human S · Phase II · Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$746K
- Private capital raisedForm D · SEC · 2nd filing$9.4M
- Private capital raisedForm D · SEC · 1st filing$3.2M
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$225K
- Federal grantHealth and Human S · Phase I · Development of a novel highly effective influenza vaccine$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#251 · top 49%
- Granted patents#14 · top 3%
- Linked publications#74 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Pamuk V. BilselResearcherExecutive OfficerLinked by 3 patents · $3.8M in grants as PI
- Bryan F. RenkDirectorNamed in SEC Form D filings
- C. Boyd ClarkeDirectorNamed in SEC Form D filings
- Craig M. HeimDirectorNamed in SEC Form D filings
- Dan Boyd StinchcombDirectorNamed in SEC Form D filings
- David G. NewbergDirectorNamed in SEC Form D filings
Show all 21 people
- David G. WalshDirectorNamed in SEC Form D filings
- Deven R. McGlennDirectorNamed in SEC Form D filings
- Eric G. PatzerDirectorNamed in SEC Form D filings
- Erik G. IversonDirectorNamed in SEC Form D filings
- Frederick V. MancheskiDirectorNamed in SEC Form D filings
- Gabriele V. NeumannDirectorNamed in SEC Form D filings
- Michael M. WagnerDirectorNamed in SEC Form D filings
- Paul V. RadspinnerExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Paul G. WeissDirectorNamed in SEC Form D filings
- Phillip M. HalpernDirectorNamed in SEC Form D filings
- Russell R. SmestadDirectorNamed in SEC Form D filings
- Scott L. KlugDirectorNamed in SEC Form D filings
- Terence F. KellyDirectorNamed in SEC Form D filings
- Terrence V. KellyDirectorNamed in SEC Form D filings
- Yoshihiro V. KawaokaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 40- PendingInfluenza B Virus Mutants And Uses ThereforUSPTOApplication 19277715
- GrantedVaccine Using M2/BM2-DEFICIENT Influenza VectorsUSPTOUS 12,728,160
- PendingInfluenza Virus BackboneUSPTOApplication 19576157
Show all 40 patent records
- Influenza B Virus Mutants And Uses ThereforSep 10, 2026 · Application 19277715Pending
- Vaccine Using M2/BM2-DEFICIENT Influenza VectorsSep 8, 2026 · US 12,728,160Granted
- Influenza Virus BackboneJul 9, 2026 · Application 19576157Pending
- Influenza Virus BackboneJul 2, 2026 · Application 19569817Pending
- Immunogenic Compositions Against InfluenzaJun 11, 2026 · Application 19193698Pending
- Influenza Virus BackboneMay 5, 2026 · US 12,616,745Granted
- Influenza Virus BackboneApr 21, 2026 · US 12,606,804Granted
- Influenza B Virus Mutants And Uses ThereforAug 19, 2025 · US 12,390,519Granted
- Immunogenic Compositions Against InfluenzaMay 27, 2025 · US 12,311,020Granted
- Influenza Virus Mutants And Uses ThereforMar 20, 2025 · Application 18629503Pending
- Influenza Virus Mutants And Uses ThereforMay 14, 2024 · US 11,980,661Granted
- Influenza Virus Vectors And Uses ThereforMay 14, 2024 · US 11,980,662Granted
- Vaccine Using M2/BM2-DEFICIENT Influenza VectorsAug 17, 2023 · Application 18017371Pending
- Influenza B Virus Mutants And Uses ThereforDec 20, 2022 · US 11,529,409Granted
- Immunogenic Compositions Against InfluenzaMay 31, 2022 · US 11,344,616Granted
- Influenza Virus Vectors And Uses ThereforFeb 22, 2022 · US 11,253,584Granted
- Influenza Virus Mutants And Uses ThereforDec 28, 2021 · US 11,207,399Granted
- Influenza Virus Mutants And Uses ThereforJun 22, 2021 · US 11,040,098Granted
- Influenza Virus Vectors And Uses ThereforDec 10, 2019 · US 10,500,267Granted
- Influenza Virus Mutants And Uses ThereforMar 20, 2018 · US 9,919,043Granted
- Influenza Virus Mutants And Uses ThereforMar 20, 2018 · US 9,919,042Granted
- Influenza Virus Vectors And Uses ThereforSep 12, 2017 · US 9,757,446Granted
- Multiple Drug Delivery DeviceDec 26, 2013 · Application 13926082Pending
- Influenza B Virus Mutants And Uses ThereforApplication PCTUS2018019690Pending
- Immunogenic Compositions Against InfluenzaApplication PCTUS2018019653Pending
- Influenza Virus BackboneApplication 62858737Pending
- Influenza Virus BackboneApplication PCTUS2020036455Pending
- Influenza Virus BackboneApplication 63054676Pending
- Vaccine Using M2/BM2-DEFICIENT Influenza VectorsApplication 63054700Pending
- Immunogenic Compositions Against InfluenzaApplication 62464019Pending
- Influenza B Virus Mutants And Uses ThereforApplication 62463994Pending
- Vaccine Using M2/BM2-DEFICIENT Influenza VectorsApplication PCTUS2021042561Pending
- Influenza Virus BackboneApplication PCTUS2021042572Pending
- Formulations For Thermostable VaccinesApplication 63589541Pending
- Influenza Virus Vectors And Uses ThereforApplication PCTUS2015020580Pending
- Multiple Drug Delivery DeviceApplication PCTUS2013047545Pending
- Formulations For Thermostable VaccinesApplication PCTUS2024051061Pending
- Influenza Virus Mutants And Uses ThereforApplication PCTUS2012043606Pending
- Wearable Drug Delivery Device Having Spring Drive And Sliding Actuation MechanismApplication PCTUS2011059066Pending
- Drug Delivery DeviceApplication PCTUS2011020113Pending
Recent research by its founders
- Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial202412 cites
- Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge20245 cites
- Intranasal M2SR and BM2SR Vaccine Viruses Do Not Shed or Transmit in Ferrets20243 cites
Related companies, and why
- Aqualung Therapeutics Corp.Similar federal contract value in Biotech · null in contracts
- AGEX THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- THIRD ELEMENT BIO INC.Similar federal contract value in Biotech · null in contracts
- ZEBRA BIOLOGICS INCSimilar federal contract value in Biotech · null in contracts
- CAPRICOR, INC.Similar federal contract value in Biotech · null in contracts
- ONCOTRAP INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .